Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates
about
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug usersPer-event probability of hepatitis C infection during sharing of injecting equipmentSequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens.Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfectionIncidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohortPotential impact of vaccination on the hepatitis C virus epidemic in injection drug users.Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index.Hepatitis C virus-specific T-cell immune responses in seronegative injection drug usersInterferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyInduction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infectionAssessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series reportPatient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients.Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012.The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus InfectionFactors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 studyAssociation of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug usersTraceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay.Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomesHepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 StudyResponse to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification.Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccinePrevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive preventionHigh rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionTreatment of acute HCV infection.Identifying newly acquired cases of hepatitis C using surveillance: a literature review.Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys.Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV InfectionDifferentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: a population-level tool for incidence estimation.A prospective study of hepatitis C incidence in Australian prisoners.
P2860
Q28476518-DCECCED1-56BD-42C5-830C-7D05E305C378Q28540414-718D9408-3BE4-4A33-86FB-114C168FFA65Q30407004-6529E636-4894-49F0-832D-8C3148F059B8Q30713067-88A70D3F-8D9C-48E6-B3D8-69F2C3136682Q33631170-D252F73A-AC83-454A-B011-3434AD569C80Q33650138-9487AA18-3D91-40F8-878A-7AA30E45441CQ33724826-F6D0BCEE-301F-45DD-8934-6F21BCFC7E9CQ33824723-4CD522F9-C175-45FD-B2D9-CFEB384E62ECQ34028058-0569C725-4F7F-424D-8790-C862BB2964E2Q34101320-02CB3FFF-BD40-4971-AF8C-00681A8FEC89Q34381567-0640B9E1-B0B5-4BE3-8A4B-7C1C00A3991FQ34785317-EDF37FC7-D316-447A-84D6-135FB747B391Q34982096-42B39FCB-C829-4D2C-A5AB-A675ECC30EB5Q35118973-DB413B2C-1042-4EEB-8E81-592A9E0E9AFEQ35138230-DAAA6470-E5F8-42D0-93D7-C278D44D4360Q35249648-C3735619-F6E6-4B24-9063-6ED3A515783FQ35551683-8D6C3B79-476A-4E79-BB94-F21FC1A0545FQ35593482-F78159DC-9760-4F76-AE53-E8A1356910E0Q35641523-39C8AC9A-4EAA-458D-8E96-A578E7AACF18Q35832850-AADEFA94-63A1-49C5-BBE4-9A1E9662E779Q35864200-E754F8AB-8044-4795-9D3D-EEE308E0DDC1Q35910953-5CA824B7-BEB2-4EBF-8798-5CFAC5EF4539Q36058580-53DD42E4-543A-49C3-BA6D-3C553822553BQ36148971-284B607E-8550-4DD0-AA48-28B6225A0D54Q36200292-CECB0917-DED4-464E-9D3F-A997E896EC49Q36433960-529608FD-1E0C-4F19-90F0-37FF1E50E16DQ36717008-127E75D0-C525-46E9-A4F8-A829676EA4E9Q36783211-C5232AAB-13CA-4C83-A200-1A78893A6EF4Q37042431-F0F94C57-CE21-444D-842C-31F9B3F663C0Q37288631-D730D921-E1AB-4316-B702-42CC8EA5738EQ37678136-E2BA976C-6427-492E-AA22-C6876C4653CCQ37855530-8C977508-30D3-4705-98F4-A74DCFFDA924Q38014990-F01B3D8C-87CD-4A9C-B2A6-CC95012EF442Q38403672-B456E692-92DC-49F3-AD3C-BA7B84E6BB11Q40466502-23BF6721-D226-44AB-8230-A3459B3B2AB9Q40563923-9DDC0996-82F6-4617-AB50-9388E79A6154Q40659995-CDC8D016-926A-4585-9BC9-D192FCDE1937Q40832940-726CDE5A-3376-43A4-8735-DE762D9A44A2Q41488562-6FE936E0-150B-42B0-9522-0C04C5E9C068Q42213249-AA77B83A-B6FA-4D8F-9B9D-17CD6CC48431
P2860
Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates
description
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2008-02)
@fr
articolo scientifico (pubblicato il 2008-02)
@it
artigo científico (publicado na 2008-02)
@pt
artículu científicu espublizáu en 2008
@ast
im Februar 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: February 2008)
@en
vedecký článok (publikovaný 2008-02)
@sk
vetenskaplig artikel (publicerad på 2008-02)
@sv
name
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@ast
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@en
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@nl
type
label
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@ast
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@en
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@nl
prefLabel
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@ast
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@en
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@nl
P2093
P2860
P356
P1476
Testing Strategy To Identify C ...... To Project HCV Incidence Rates
@en
P2093
Andrew R Moss
Brandee L Pappalardo
Bruce H Phelps
David J Wright
Kimberly Page-Shafer
Leslie H Tobler
Sally Caglioti
Teresa L Wright
Thomas R O'Brien
P2860
P304
P356
10.1128/JCM.01229-07
P407
P577
2008-02-01T00:00:00Z